Skip to site content

COVID-19 Rebound After Paxlovid Treatment

The Centers for Disease Control and Prevention (CDC) released a Health Advisory Network (HAN) Health Advisory Exit Disclaimer: You Are Leaving www.ihs.gov  on the potential for recurrence of COVID-19 or “COVID-19 rebound.”

Recent case reports document that some patients with normal immune response who have completed a 5-day course of Paxlovid for laboratory confirmed infection and have recovered can experience recurrent illness 2 to 8 days later, including patients who have been vaccinated and/or boosted. Both the recurrence of illness and positive test results improved or resolved (median of 3 days) without additional anti-COVID-19 treatment. Based on information from the case reports, COVID-19 rebound did not represent reinfection with SARS-CoV-2 or the development of resistance to Paxlovid; also, no other respiratory pathogens were identified among known cases.

Covid-19 infection to 5-day course of Paxlovid. 2 to 8 days later a positive COVID test to Covid-19 rebound.

There was no increased occurrence of hospitalization or death.It remains unknown whether the likelihood of possible transmission of infection during COVID-19 rebound differs from the likelihood oftransmission during the initial infection, therefor patients with COVID-19 rebound are encouraged to follow CDC’s guidance on isolation Exit Disclaimer: You Are Leaving www.ihs.gov .

Recommendations for Healthcare Providers